You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 16, 2025

CLINICAL TRIALS PROFILE FOR EPHEDRINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ephedrine Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00426842 ↗ A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride Completed James J. Peters Veterans Affairs Medical Center Phase 2 2007-01-01 With upright postures, there is an immediate redistribution of blood to the dependent circulation; venous return and central venous filling pressure are reduced, resulting in diminution of cardiac output and blood pressure. These hemodynamic alterations stimulate the baroreceptor reflex, which is mediated via the central nervous system to increase peripheral sympathetic vasomotor tone, restoring blood pressure and cardiac output within seconds-to-minutes of the assumption of the upright position. Following SCI, individuals often experience the inability to adjust to postural changes due to disruption of central command of the baroreceptor reflex and reduction in efferent sympathetic neural pathways; consequently, orthostatic hypotension (OH) and symptoms of cerebral hypo-perfusion may ensue. OH is a well-documented phenomenon, which is characterized by a fall in systolic blood pressure of >20 mmHg or diastolic BP of > 10 mmHg within 3 minutes of assumption of an upright posture. As a consequence of OH, many individuals experience symptoms of cerebral hypo-perfusion which include lightheadedness, dizziness, blurry vision, fatigue, nausea, ringing in the ears, cognitive impairment and heart palpitations. Although several investigators have reported increased prevalence of OH during the acute phase of spinal cord injury (SCI), individuals with chronic injury also experience significant falls in blood pressure with seated upright postures. This investigation will examine the effects of an alpha-agonist, midodrine hydrochloride, during head-up tilt on systemic blood pressure, cerebral blood flow and cerebral oxygenation compared to placebo administration in persons with chronic SCI who demonstrate significant orthostatic hypotension during a 24-hour observation study. This is the first study to determine the dose response and efficacy of midodrine to improve orthostatic blood pressure and cerebral blood flow and oxygenation in the SCI population.
NCT00458003 ↗ Phenylephrine in Spinal Anesthesia in Preeclamptic Patients Completed Northwestern University N/A 2006-07-01 Hypotension remains a common clinical problem after induction of spinal anesthesia for cesarean delivery. Maternal hypotension has been associated with considerable morbidity (maternal nausea and vomiting and fetal/neonatal acidemia). Traditionally, ephedrine has been the vasopressor of choice because of concerns about phenylephrine's potential adverse effect on uterine blood flow. This practice was based on animal studies which showed that ephedrine maintained cardiac output and uterine blood flow, while direct acting vasoconstrictors, e.g., phenylephrine, decreased uteroplacental perfusion. However, several recent studies have demonstrated that phenylephrine has similar efficacy to ephedrine for preventing and treating hypotension and may be associated with a lower incidence of fetal acidosis. All of these studies have been performed in healthy patients undergoing elective cesarean delivery. Preeclampsia complicates 5-6% of all pregnancies and is a significant contributor to maternal and fetal morbidity and mortality. Many preeclamptic patients require cesarean delivery of the infant. These patients often have uteroplacental insufficiency. Given the potential for significant hypotension after spinal anesthesia and its effect on an already compromised fetus, prevention of (relative) hypotension in preeclamptic patients is important. Spinal anesthesia in preeclamptic patients has been shown to have no adverse neonatal outcomes as compared to epidural anesthesia when hypotension is treated adequately. Due to problems related to management of the difficult airway and coagulopathy, both of which are more common in preeclamptic women, spinal anesthesia may be the preferred regional anesthesia technique. Recent studies have demonstrated that preeclamptic patients may experience less hypotension after spinal anesthesia than their healthy counterparts. To our knowledge, phenylephrine for the treatment of spinal anesthesia-induced hypotension has not been studied in women with preeclampsia. The aim of our study is to compare intravenous infusion regimens of phenylephrine versus ephedrine for the treatment of spinal anesthesia induced hypotension in preeclamptic patients undergoing cesarean delivery. The primary outcome variable is umbilical artery pH.
NCT01006863 ↗ Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study Completed Mansoura University Phase 2 2004-03-01 The prophylactic use of small doses of ephedrine may be effective in obtunding of the hypotension responses to propofol with minimal hemodynamic and ST segment changes. The investigators aimed to evaluate the effects of small doses of ephedrine on hemodynamic responses of propofol anesthesia for valve surgery. There is widespread interest in the use of propofol for the induction and maintenance of anesthesia for fast track cardiac surgery. However, its use for induction of anesthesia is often associated with a significant rate related transient hypotension for 5-10 minutes. This is mainly mediated with decrease in sympathetic activity with minor contribution of its direct vascular smooth muscle relaxation and direct negative inotropic effects. Ephedrine has demonstrated as a vasopressor drug for the treatment of hypotension in association with spinal and general anesthesia. Prophylactic use of high doses of ephedrine [10-30 mg] was effective in obtunding the hypotensive response to propofol with associated marked tachycardia. However, the use of smaller doses (0.1-0.2 mg/kg) was successfully attenuated, but not abolished, the decrease in blood pressure with transient increase in heart rate. This vasopressor effect is mostly mediated by β-stimulation rather than α-stimulation and also indirectly by releasing endogenous norepinephrine from sympathetic nerves. Because the effect of decreasing the dose of ephedrine from 0.1 to 0.07 mg/kg may be clinically insignificant, the investigators postulated that the prophylactic use of small dose of ephedrine may prevent propofol-induced hypotension after induction of anesthesia for valve surgery with minimal in hemodynamic, ST segment, and troponin I changes. The aim of the present study was to investigate the effects of pre-induction administration of 0.07, 0.1, 0.15 mg/kg of ephedrine on heart rate (HR), mean arterial blood pressure (MAP), central venous and pulmonary artery occlusion pressures (CVP and PAOP, respectively), cardiac (CI), stroke volume (SVI), systemic and pulmonary vascular resistance (SVRI and PVRI, respectively), left and right ventricular stroke work (LVSWI and RVSWI, respectively) indices, ST segment, and cardiac troponin I (cTnI) changes in the patients anesthetized with propofol-fentanyl for valve surgery.
NCT01006863 ↗ Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study Completed King Faisal University Phase 2 2004-03-01 The prophylactic use of small doses of ephedrine may be effective in obtunding of the hypotension responses to propofol with minimal hemodynamic and ST segment changes. The investigators aimed to evaluate the effects of small doses of ephedrine on hemodynamic responses of propofol anesthesia for valve surgery. There is widespread interest in the use of propofol for the induction and maintenance of anesthesia for fast track cardiac surgery. However, its use for induction of anesthesia is often associated with a significant rate related transient hypotension for 5-10 minutes. This is mainly mediated with decrease in sympathetic activity with minor contribution of its direct vascular smooth muscle relaxation and direct negative inotropic effects. Ephedrine has demonstrated as a vasopressor drug for the treatment of hypotension in association with spinal and general anesthesia. Prophylactic use of high doses of ephedrine [10-30 mg] was effective in obtunding the hypotensive response to propofol with associated marked tachycardia. However, the use of smaller doses (0.1-0.2 mg/kg) was successfully attenuated, but not abolished, the decrease in blood pressure with transient increase in heart rate. This vasopressor effect is mostly mediated by β-stimulation rather than α-stimulation and also indirectly by releasing endogenous norepinephrine from sympathetic nerves. Because the effect of decreasing the dose of ephedrine from 0.1 to 0.07 mg/kg may be clinically insignificant, the investigators postulated that the prophylactic use of small dose of ephedrine may prevent propofol-induced hypotension after induction of anesthesia for valve surgery with minimal in hemodynamic, ST segment, and troponin I changes. The aim of the present study was to investigate the effects of pre-induction administration of 0.07, 0.1, 0.15 mg/kg of ephedrine on heart rate (HR), mean arterial blood pressure (MAP), central venous and pulmonary artery occlusion pressures (CVP and PAOP, respectively), cardiac (CI), stroke volume (SVI), systemic and pulmonary vascular resistance (SVRI and PVRI, respectively), left and right ventricular stroke work (LVSWI and RVSWI, respectively) indices, ST segment, and cardiac troponin I (cTnI) changes in the patients anesthetized with propofol-fentanyl for valve surgery.
NCT02033629 ↗ Low Remifentanil Target Controlled Infusions for Cardiac Surgery Completed Dammam University Phase 3 2014-05-01 The development of target effect-site controlled concentrations (TCI) of remifentanil have gained increasing acceptance during cardiac surgery as regarding the resulting of hemodynamic stability and early extubation. The use of low-dose opioid technique has been progressively used nowadays because of its ceiling effect to attenuate cardiovascular responses to noxious stimuli. We hypothesize that the use of low target remifentanil effect site concentrations may provide comparable shorter times to tracheal extubation and hemodynamic stability to the use of high remifentanil Ce during target-controlled propofol anesthesia for cardiac surgery.
NCT02296333 ↗ Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen Completed Mustafa Kemal University Phase 4 2014-05-01 The purpose of the study is to determine whether the effect of ondansetron on the analgesic effect of acetaminophen. Because 5HT3 blockers prevent the analgesic effects of acetaminophen and also reduce opioid consumption
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ephedrine Sulfate

Condition Name

Condition Name for Ephedrine Sulfate
Intervention Trials
Hypotension 2
Pain, Postoperative 2
Spinal Cord Injury 1
Magnesium Sulfate 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ephedrine Sulfate
Intervention Trials
Pain, Postoperative 4
Hypotension 3
Rectal Diseases 1
Pre-Eclampsia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ephedrine Sulfate

Trials by Country

Trials by Country for Ephedrine Sulfate
Location Trials
Egypt 7
Saudi Arabia 2
United States 2
Mexico 1
Greece 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ephedrine Sulfate
Location Trials
Illinois 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ephedrine Sulfate

Clinical Trial Phase

Clinical Trial Phase for Ephedrine Sulfate
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ephedrine Sulfate
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ephedrine Sulfate

Sponsor Name

Sponsor Name for Ephedrine Sulfate
Sponsor Trials
Ain Shams University 2
Mansoura University 2
Dammam University 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ephedrine Sulfate
Sponsor Trials
Other 14
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ephedrine Sulfate: Clinical Trials, Market Analysis, and Projections

Introduction to Ephedrine Sulfate

Ephedrine sulfate is a small molecule drug that acts as both an α-adrenergic receptor agonist and a β-adrenoceptor agonist. It is primarily used in the treatment of cardiovascular diseases, particularly hypotension, and has various other medical applications.

Clinical Trials and Approval

Ephedrine sulfate was first approved in the United States in April 2016 by the U.S. Food and Drug Administration (FDA) for its safety and effectiveness in treating hypotension[4].

A notable clinical study conducted by the Medical College of Wisconsin (MCW) School of Pharmacy and Nexus Pharmaceuticals, Inc. compared the use of EMERPHED™, a ready-to-use ephedrine sulfate product, with commercially available concentrated ephedrine sulfate. The study, conducted in an operating room setting, showed that EMERPHED™ had significantly greater compounding efficacy and ease of use, reducing the risk of error compared to the concentrated form[1].

Mechanism of Action

Ephedrine sulfate works by stimulating both α-adrenergic and β-adrenergic receptors, which enhances the release of norepinephrine. This action is crucial in managing and treating clinically significant hypotension, particularly that induced by spinal or epidural anesthesia. It is also used for relieving acute bronchospasm and treating conditions such as bronchial asthma, urinary incontinence, heart failure, and rhinitis[4].

Market Analysis

Market Size and Growth

The global ephedrine sulfate market is projected to witness a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2024 to 2031. The market is expected to grow from USD 122.45 million in 2023 to USD 196.64 million by 2031[2][5].

Key Drivers of Market Growth

  1. Increasing Prevalence of Hypotension During Spinal Anesthesia:

    • Hypotension is a common complication during spinal anesthesia, with a study showing it occurred in 76% of cases during cesarean sections. Ephedrine is the agent of choice for managing this condition, thus driving demand for ephedrine sulfate[2][5].
  2. Rising Cases of Bronchial Asthma:

    • The increase in asthma cases, with approximately 7.7% of Americans (24.9 million people) suffering from asthma in 2023, is another significant factor. Ephedrine sulfate is used to relieve acute bronchospasm and manage mild symptoms of intermittent asthma[2][5].
  3. Expansion of the Pharmaceutical Sector:

    • The rapid growth of the pharmaceutical industry globally, particularly in regions like India and the UK, is boosting the demand for ephedrine sulfate. The Indian pharmaceutical industry is expected to reach USD 130 billion by 2030, and the UK's pharmaceutical industry has a turnover of USD 51.7 billion[2][5].

Regional Market Share

  • North America: This region holds a significant market share, accounting for 49.1% of global pharmaceutical sales in 2021. The high demand for pharmaceutical products in this region contributes to the increased requirement for ephedrine sulfate[2].

Market Projections

Forecast Period

The market is expected to grow substantially over the forecast period from 2024 to 2031, driven by the increasing prevalence of conditions such as hypotension and bronchial asthma, as well as the expansion of the pharmaceutical sector.

Research and Development

The ongoing research and development activities aimed at testing the efficacy of treatment solutions derived from ephedrine sulfate will further boost market expansion. These activities are crucial for exploring new therapeutic applications and enhancing patient outcomes[2][5].

Patient Safety and Ease of Use

The study by MCW and Nexus Pharmaceuticals highlighted that EMERPHED™, a ready-to-use ephedrine sulfate product, offers greater compounding efficacy and ease of use compared to concentrated ephedrine sulfate. This reduces the risk of error in clinical settings, reinforcing patient safety[1].

Conclusion

Ephedrine sulfate is a critical drug in the management of hypotension and other cardiovascular conditions, as well as in treating bronchial asthma. The market for ephedrine sulfate is poised for significant growth driven by increasing medical needs and the expansion of the pharmaceutical sector. The ease of use and safety profile of ready-to-use formulations like EMERPHED™ further support its adoption in clinical settings.

Key Takeaways

  • Clinical Approval: Ephedrine sulfate was approved by the FDA in 2016 for treating hypotension.
  • Market Growth: The global ephedrine sulfate market is expected to grow at a CAGR of 6.1% from 2024 to 2031.
  • Key Drivers: Increasing prevalence of hypotension during spinal anesthesia, rising cases of bronchial asthma, and expansion of the pharmaceutical sector.
  • Patient Safety: Ready-to-use formulations like EMERPHED™ enhance patient safety by reducing the risk of error.
  • Regional Market: North America holds a significant market share due to high pharmaceutical sales.

FAQs

What is the primary therapeutic use of ephedrine sulfate?

Ephedrine sulfate is primarily used in the treatment of cardiovascular diseases, specifically hypotension, and is also used for managing bronchial asthma and other conditions[4].

What is the projected growth rate of the global ephedrine sulfate market?

The global ephedrine sulfate market is projected to witness a CAGR of 6.1% during the forecast period from 2024 to 2031[2][5].

Which regions are driving the demand for ephedrine sulfate?

North America and Europe are significant regions driving the demand for ephedrine sulfate, with North America accounting for 49.1% of global pharmaceutical sales in 2021[2].

What are the advantages of ready-to-use ephedrine sulfate formulations?

Ready-to-use formulations like EMERPHED™ offer greater compounding efficacy and ease of use, reducing the risk of error in clinical settings and enhancing patient safety[1].

How does ephedrine sulfate work?

Ephedrine sulfate works by stimulating both α-adrenergic and β-adrenergic receptors, enhancing the release of norepinephrine, which is crucial in managing hypotension and other conditions[4].

Sources

  1. Medical College of Wisconsin: Study of EMERPHED™ (Ephedrine Sulfate) Ready-to-Use Injection Results Reinforce Patient Safety.
  2. Market Xcel - Markets and Data: Global ephedrine sulfate market assessment.
  3. FDA: 213407Orig1s000ChemR.pdf.
  4. Synapse by Patsnap: Ephedrine Sulfate's R&D Progress and its Mechanism of Action.
  5. MarketsandData: Ephedrine Sulfate Market Size, Trends And Forecast To 2031.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.